Clinical Trials in Netherlands 2026 - 105 Recent EU Authorisations

Phase I Diagnosis Authorised 10/09/2026

Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)

Bone Morphogenic Protein Receptor type 2 mutation carriers Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Metabolic dysfunction-associated Steatotic Liver Disease Pulmonary Arterial Hypertension Primary Sclerosing Cholangitis

Amsterdam UMC Stichting

57 participants planned

Netherlands

2025-521143-20-00 on CTIS ↗

Phase III Neoplasms Authorised 08/09/2026

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)

Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy

Amgen Inc.

54 participants planned

Netherlands · Hungary · Portugal · France · Belgium

2026-525489-23-00 on CTIS ↗

Phase I Metabolism Authorised 04/09/2026

A Phase 1 study of a novel sublingual insulin formulation

Type 1 diabetes mellitus

Sublin B.V.

19 participants planned

Netherlands

2025-521863-11-00 on CTIS ↗

Phase II Behavior and Behavior Mechanisms Authorised 02/09/2026

Propranolol Dosefinding Assessment in Reactive Aggression Treatment (PRO-DART)

Reactive aggression

Radboud universitair medisch centrum Stichting

30 participants planned

Netherlands

2026-526545-95-00 on CTIS ↗

Phase III Immune System Diseases Authorised 02/09/2026

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

Immune system diseases

Sanofi-Aventis Recherche & Developpement

338 participants planned

Belgium · Czechia · Hungary · Sweden · Lithuania · Croatia · Netherlands · Slovakia · Poland · Austria · Norway · France · Italy · Bulgaria · Spain · Germany · Romania · Slovenia · Estonia · Portugal · Greece · Denmark

2026-525913-30-00 on CTIS ↗

Phase II Eye Diseases Authorised 01/09/2026

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Dompe' Farmaceutici S.p.A.

171 participants planned

Denmark · Italy · Germany · Hungary · Netherlands · Spain · Belgium · France · Portugal

2025-524748-37-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 01/09/2026

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

GBA1-associated Parkinson’s disease

Vanqua Bio Inc.

16 participants planned

Netherlands · France · Spain · Germany

2026-525848-15-00 on CTIS ↗

Phase IV Digestive System Diseases Authorised 01/09/2026

Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study

Eosinophilic Esophagitis

Amsterdam UMC Stichting

160 participants planned

Netherlands

2026-526348-11-01 on CTIS ↗

Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 31/08/2026

A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT)

Vaderis Therapeutics AG

130 participants planned

Hungary · Netherlands · Germany · Bulgaria · France · Italy · Lithuania · Spain · Belgium

2025-524490-17-00 on CTIS ↗

Phase II Neoplasms Authorised 31/08/2026

In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint

Unresectable stage III non-small cell lung cancer

Universitair Medisch Centrum Groningen

20 participants planned

Netherlands

2026-526251-60-00 on CTIS ↗

Phase II Hemic and Lymphatic Diseases Authorised 31/08/2026

HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL)

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

276 participants planned

Czechia · Denmark · Croatia · Spain · Sweden · Finland · Portugal · Ireland · Netherlands · Belgium · Norway

2025-524230-25-00 on CTIS ↗

Phase III Neoplasms Authorised 28/08/2026

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER

Resected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer

F. Hoffmann-La Roche AG

178 participants planned

France · Spain · Austria · Greece · Portugal · Belgium · Italy · Germany · Netherlands

2025-524263-21-01 on CTIS ↗

Phase I/II Neoplasms Authorised 27/08/2026

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)

Institut De Recherches Internationales Servier IRIS

38 participants planned

Netherlands · Spain · Germany · Italy · France · Finland

2025-525128-88-00 on CTIS ↗

Phase II Mental Disorders Authorised 26/08/2026

MDMA-assisted therapy for adolescents with treatment-resistant PTSD

Post-traumatic stress disorder

Stichting Amsterdam UMC

12 participants planned

Netherlands

2024-515184-65-01 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 26/08/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

Contineum Therapeutics Inc.

156 participants planned

Italy · Belgium · Denmark · Austria · Greece · Germany · France · Netherlands · Portugal · Poland · Spain

2025-521901-42-00 on CTIS ↗

Phase II Neoplasms Authorised 26/08/2026

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Gastrointestinal Cancers

Genmab A/S

67 participants planned

Italy · Belgium · France · Spain · Denmark · Netherlands · Germany

2025-524130-26-00 on CTIS ↗

Phase II Neoplasms Authorised 25/08/2026

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

Solid tumor

Bristol-Myers Squibb Services Unlimited Company

116 participants planned

Greece · Hungary · Poland · Belgium · Spain · Netherlands · Germany · France · Portugal · Italy · Romania

2025-524905-34-00 on CTIS ↗

Phase III Neoplasms Authorised 24/08/2026

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Pancreatic Adenocarcinoma

Revolution Medicines Inc.

281 participants planned

Sweden · Spain · France · Poland · Italy · Norway · Belgium · Germany · Czechia · Austria · Netherlands · Denmark

2025-524928-21-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 21/08/2026

A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy

Focal epilepsy

Ovid Therapeutics Inc.

6 participants planned

Netherlands

2026-525896-23-00 on CTIS ↗

Phase III Neoplasms Authorised 21/08/2026

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Gastrointestinal Stromal

Glaxosmithkline Research & Development Limited

302 participants planned

Italy · Portugal · Germany · Sweden · Poland · Romania · Finland · Greece · Norway · Spain · Netherlands · France · Hungary

2025-524934-24-00 on CTIS ↗

Phase I Not possible to specify Authorised 21/08/2026

A study to see how safe a new medicine (NNC0705-0002) is in healthy people

Cardiometabolic

Novo Nordisk A/S

112 participants planned

Netherlands

2026-526205-15-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 21/08/2026

A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)

Recurrent Glioblastoma

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

18 participants planned

Netherlands

2025-524555-31-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 18/08/2026

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Elevated lipoprotein(a)

Merck Sharp & Dohme LLC

295 participants planned

Netherlands · Denmark · Germany · Spain

2025-525102-38-00 on CTIS ↗

Phase III Neoplasms Authorised 17/08/2026

Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)

Small-cell lung cancer, limited stage

Norges Teknisk-Naturvitenskapelige Universitet NTNU

426 participants planned

Denmark · Finland · Estonia · Germany · Lithuania · Sweden · Norway · Netherlands

2026-525513-31-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 14/08/2026

A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

heart failure

Cardurion Pharmaceuticals Inc.

369 participants planned

Latvia · Slovakia · Lithuania · Hungary · Italy · Netherlands · Spain · Poland · Bulgaria · Czechia

2025-525033-31-00 on CTIS ↗

Phase I/II Digestive System Diseases Authorised 12/08/2026

Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)

Lynch Syndrome

Radboud universitair medisch centrum Stichting

13 participants planned

Netherlands

2025-524046-10-00 on CTIS ↗

Phase I Neoplasms Authorised 11/08/2026

A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors

Locally Advanced or Metastatic Solid Tumors

Exelixis Inc.

40 participants planned

Italy · Netherlands · France · Spain

2025-524805-34-00 on CTIS ↗

Phase I Neoplasms Authorised 11/08/2026

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Advanced solid tumors

Pfizer Inc.

52 participants planned

Netherlands · France · Spain

2025-522532-14-00 on CTIS ↗

Phase I/II Parasitic Diseases Authorised 10/08/2026

Evaluation of Interference and Synergy of Anti-Circumsporozoite Antibodies on GA2-induced Immunity

Plasmodium falciparum malaria

Leids Universitair Medisch Centrum (LUMC)

33 participants planned

Netherlands

2026-525353-37-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 10/08/2026

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

Overweight and obesity

Novo Nordisk A/S

315 participants planned

Netherlands · Belgium · Greece · Poland · Spain · Denmark · France · Bulgaria · Sweden

2025-524626-18-00 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 06/08/2026

[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

Atrial fibrillation

Bayer AG

105 participants planned

Belgium · Netherlands · Germany · Poland · Italy · Hungary · Bulgaria

2025-523807-31-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 04/08/2026

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES), Asthma

AstraZeneca AB

94 participants planned

Denmark · Belgium · France · Italy · Netherlands · Austria · Poland

2025-523307-29-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 04/08/2026

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

Idiopathic Pulmonary Fibrosis

AstraZeneca AB

139 participants planned

Poland · Hungary · Netherlands · Germany · Spain · Greece · Bulgaria · Italy · France · Denmark

2025-525016-41-00 on CTIS ↗

Phase III Skin and Connective Tissue Diseases Authorised 03/08/2026

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Systemic sclerosis

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

179 participants planned

Denmark · Hungary · Sweden · Netherlands · Germany · Belgium · France · Greece · Norway · Finland · Czechia · Portugal · Bulgaria · Spain · Austria · Romania · Croatia · Poland · Estonia · Italy · Lithuania

2025-523884-39-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 03/08/2026

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

Epilepsy

Ovid Therapeutics Inc.

12 participants planned

Netherlands

2026-527114-23-00 on CTIS ↗

Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

194 participants planned

Norway · Romania · Austria · Italy · Slovakia · Germany · Hungary · Netherlands · Belgium · France · Portugal · Czechia · Poland · Spain · Greece

2026-525922-39-00 on CTIS ↗

Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis

Janssen Cilag International

302 participants planned

France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal

2026-525923-26-00 on CTIS ↗

Phase I Pathological Conditions, Signs and Symptoms Authorised 30/07/2026

Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer

HER2 mutation positive NSCLC

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

20 participants planned

Netherlands

2026-525568-17-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 30/07/2026

Nav 1.8 and 1.7 combo trial

Pain

Niroda Therapeutics Inc.

96 participants planned

Netherlands

2026-526867-39-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 30/07/2026

J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases

Eli Lilly & Co.

145 participants planned

Hungary · Czechia · Spain · Netherlands

2025-524858-34-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 29/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF); on background SGLT2i.

AstraZeneca AB

2343 participants planned

Spain · Hungary · Germany · Poland · Italy · Bulgaria · Netherlands · Austria · Romania · Sweden · France · Greece · Slovakia · Czechia

2026-526304-79-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

Participants with obesity with or without type 2 diabetes

Novo Nordisk A/S

1140 participants planned

Greece · Portugal · France · Slovakia · Bulgaria · Netherlands · Romania · Italy · Austria · Poland · Hungary · Spain · Czechia · Belgium

2025-522488-14-00 on CTIS ↗

Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 27/07/2026

4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

Barth Syndrome

Stealth Biotherapeutics Inc.

22 participants planned

Ireland · Netherlands · France · Italy

2025-523837-25-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 27/07/2026

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.

Atrial Fibrillation

Milestone Pharmaceuticals Inc.

200 participants planned

Netherlands

2024-516251-40-01 on CTIS ↗

Phase IV Therapeutics Authorised 24/07/2026

VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)

Parapneumonic pleural infection/pleural empyema

Amsterdam UMC Stichting

164 participants planned

Netherlands

2026-526289-25-00 on CTIS ↗

Phase IV Immune System Diseases Authorised 22/07/2026

Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?

Diabetes

Radboud universitair medisch centrum Stichting

100 participants planned

Netherlands

2026-525909-13-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 22/07/2026

A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)

Alnylam Pharmaceuticals Inc.

17 participants planned

Italy · Netherlands · Spain · Germany · Ireland

2025-523390-42-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 21/07/2026

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

Ipsen Bioscience Inc.

127 participants planned

Spain · Sweden · Germany · Romania · Finland · Portugal · Austria · Italy · Denmark · Czechia · France · Netherlands · Poland · Belgium · Norway

2026-525242-29-00 on CTIS ↗

Phase I/II Neoplasms Authorised 21/07/2026

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

Neoplasms, Prostate

Glaxosmithkline Research & Development Limited

18 participants planned

Netherlands · France · Spain

2025-523874-17-00 on CTIS ↗

Phase I Neoplasms Authorised 21/07/2026

A more sustainable perioperative treatment regimen for gastroesophageal cancer —replacing 5-FU with capecitabine within the FLOT regimen

Gastric Cancer, Esophageal cancer

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

14 participants planned

Netherlands

2026-526209-13-00 on CTIS ↗

Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

HIV-1

Gilead Sciences Inc.

183 participants planned

Poland · Italy · France · Spain · Germany · Netherlands

2025-524336-19-00 on CTIS ↗

Phase III Virus Diseases Authorised 21/07/2026

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

HIV-1

Gilead Sciences Inc.

183 participants planned

Netherlands · Poland · Germany · France · Spain · Italy

2025-524335-39-00 on CTIS ↗

Phase II Neoplasms Authorised 20/07/2026

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

58 participants planned

Netherlands

2025-524842-89-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 20/07/2026

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

Huntington’s Disease

Novartis Pharma AG

368 participants planned

Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary

2025-522227-99-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 20/07/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Narcolepsy Type 1

Alkermes Inc.

116 participants planned

Sweden · Finland · Belgium · Spain · Austria · Netherlands · France · Norway · Germany · Italy · Poland

2025-524711-36-00 on CTIS ↗

Phase III Cardiovascular Diseases Authorised 20/07/2026

Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Subjects (age 12 to <18 years) with Homozygous Familial Hypercholesterolemia (SPRUCE)

Homozygous Familial Hypercholesterolemia (HoFH)

Arrowhead Pharmaceuticals Inc.

9 participants planned

Netherlands · Denmark · Norway · Sweden · Poland

2025-523662-24-00 on CTIS ↗

Phase II Otorhinolaryngologic Diseases Authorised 17/07/2026

Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).

Oral cavity squamous cell carcinoma

Amsterdam UMC Stichting

24 participants planned

Netherlands

2025-523617-29-01 on CTIS ↗

Phase III Neoplasms Authorised 14/07/2026

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic colorectal cancer

Merck Healthcare KGaA

323 participants planned

Belgium · Germany · France · Denmark · Poland · Spain · Netherlands · Italy · Austria

2025-524648-37-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 14/07/2026

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma

Revolution Medicines Inc.

337 participants planned

Poland · Belgium · Norway · Sweden · Austria · Germany · Denmark · Netherlands · France · Italy · Spain

2025-525088-34-00 on CTIS ↗

Phase II Neoplasms Authorised 13/07/2026

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis

Recursion Pharmaceuticals Inc.

20 participants planned

Netherlands · Germany · Spain

2026-525282-50-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 13/07/2026

SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study

Cluster headache

Leids Universitair Medisch Centrum (LUMC)

26 participants planned

Netherlands

2025-523293-17-00 on CTIS ↗

Phase II Neoplasms Authorised 09/07/2026

Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma

Pleural mesothelioma

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

42 participants planned

Netherlands

2026-526036-38-00 on CTIS ↗

Phase II Immune System Diseases Authorised 08/07/2026

Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

Argenx

29 participants planned

Greece · Italy · Germany · Belgium · Netherlands · Spain · Poland

2025-522939-33-00 on CTIS ↗

Phase II Nervous System Diseases Authorised 08/07/2026

Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)

Multiple Sclerosis

Amsterdam UMC Stichting

84 participants planned

Netherlands

2026-525260-18-00 on CTIS ↗

Phase III Neoplasms Authorised 08/07/2026

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

Osteosarcoma

Institut Gustave Roussy

508 participants planned

Sweden · Poland · Denmark · Finland · Netherlands · Italy · France · Spain

2023-505575-69-01 on CTIS ↗

Phase II Cardiovascular Diseases Authorised 08/07/2026

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Female Patients with Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Alnylam Pharmaceuticals Inc.

5 participants planned

Netherlands · Sweden · Germany

2025-524967-19-00 on CTIS ↗

Phase I Neoplasms Authorised 07/07/2026

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)

Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal Neoplasms Colorectal Neoplasms Esophageal Neoplasms Stomach Neoplasms Cholangiocarcinoma

Eli Lilly & Co.

64 participants planned

Germany · Netherlands

2025-521887-37-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 07/07/2026

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

Fibrosing interstitial lung disease

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

20 participants planned

Belgium · Greece · Germany · France · Finland · Spain · Czechia · Poland · Italy · Netherlands · Denmark · Portugal

2025-523369-32-00 on CTIS ↗

Phase II Neoplasms Authorised 06/07/2026

Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I

suspected malignant pulmonary disease (lung lesions and/or lymph nodes suspicious for lung cancer)

Universitair Medisch Centrum Groningen

20 participants planned

Netherlands

2024-510793-24-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases

Sanofi-Aventis Recherche & Developpement

550 participants planned

Germany · Romania · Greece · Norway · Netherlands · Poland · Lithuania · Czechia · Slovakia · Spain

2024-518213-25-00 on CTIS ↗

Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 06/07/2026

iSTOP-CP: intranasal Stem Cells to treat Perinatal brain injury to combat Cerebral Palsy

Hypoxic-ischemic brain injury (HIBI) because of Perinatal Asphyxia (PA) or Perinatal arterial ischemic stroke (PAIS)

Universitair Medisch Centrum Utrecht

162 participants planned

Netherlands

2025-521506-17-01 on CTIS ↗

Phase III Digestive System Diseases Authorised 03/07/2026

Dual-agent fluorescence-guided surgery for colorectal liver metastases

Colorectal liver metastases

Leids Universitair Medisch Centrum (LUMC)

39 participants planned

Netherlands

2025-524755-31-00 on CTIS ↗

Phase I Neoplasms Authorised 02/07/2026

Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial

Advanced thyroid cancer

Stichting Radboud University Medical Center

10 participants planned

Netherlands

2023-507214-28-00 on CTIS ↗

Phase III Mental Disorders Authorised 01/07/2026

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)

First Episode Psychosis (FEP)

University Of Oxford

156 participants planned

Netherlands · Greece · Germany · Italy · Austria · Spain

2025-521929-32-01 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 01/07/2026

A phase 1b trial to study the safety and effect of ZP9830 in patients with plaque psoriasis

Plaque Psoriasis

Zealand Pharma A/S

32 participants planned

Netherlands

2026-525220-15-00 on CTIS ↗

Phase I Immune System Diseases Authorised 01/07/2026

A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

Rheumatoid Arthritis

AbbVie Deutschland GmbH & Co. KG

19 participants planned

Belgium · Netherlands · Spain · Germany · Italy

2025-523127-21-00 on CTIS ↗

Phase I Not possible to specify Authorised 30/06/2026

A study in healthy men to test how BI 1815368 is processed in the body

Healthy volunteers trial

Boehringer Ingelheim International GmbH

8 participants planned

Netherlands

2025-523949-10-00 on CTIS ↗

Phase IV Reproductive and Urinary Physiological Phenomena Authorised 30/06/2026

Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)

unexplained subfertillity, infertillity

Universitair Medisch Centrum Utrecht

640 participants planned

Netherlands

2026-525747-33-00 on CTIS ↗

Phase III Immune System Diseases Authorised 30/06/2026

Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)

Eosinophilic Disease

AstraZeneca AB

7 participants planned

Poland · Netherlands · France

2023-508533-14-00 on CTIS ↗

Phase I/II Respiratory Tract Diseases Authorised 29/06/2026

PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER

Non small cell lung cancer

Radboud universitair medisch centrum Stichting

40 participants planned

Netherlands · Germany

2025-524791-30-00 on CTIS ↗

Phase II Immune System Diseases Authorised 29/06/2026

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Mediar Therapeutics Inc.

36 participants planned

Netherlands · Romania · Poland · France · Italy · Spain

2025-523288-39-00 on CTIS ↗

Phase I Nervous System Diseases Authorised 26/06/2026

Three-part PK and PD study of AXN-027

Chronic pain, refractory epilepsy, and other neurological disorders of excitation/inhibition (E/I) imbalance within neuronal circuits.

Axonis Therapeutics Inc.

64 participants planned

Netherlands

2025-524019-35-00 on CTIS ↗

Phase III Digestive System Diseases Authorised 23/06/2026

ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis

liver cirrhosis

Amsterdam UMC Stichting

634 participants planned

Netherlands

2026-526167-38-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 23/06/2026

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

Non-cystic fibrosis bronchiectasis

Sanofi-Aventis Recherche & Developpement

41 participants planned

Poland · Spain · France · Netherlands · Germany

2025-523403-29-00 on CTIS ↗

Phase III Nervous System Diseases Authorised 22/06/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-active Secondary Progressive Multiple Sclerosis (SPMS)

Zenas Biopharma (USA) LLC

486 participants planned

Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece

2025-524322-18-00 on CTIS ↗

Phase II Digestive System Diseases Authorised 22/06/2026

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

Colitis ulcerative

Merck Sharp & Dohme LLC

44 participants planned

Italy · Greece · Netherlands · Poland · Germany · France

2025-523479-49-00 on CTIS ↗

Phase I/II Musculoskeletal Diseases Authorised 22/06/2026

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis

Trace Neuroscience Inc.

20 participants planned

Germany · Netherlands

2025-523111-11-00 on CTIS ↗

Phase IV Musculoskeletal Diseases Authorised 22/06/2026

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

Metachromatic leukodystrophy

Orchard Therapeutics (Europe) Limited

29 participants planned

Netherlands · Germany · Italy · Sweden · France

2025-522275-28-00 on CTIS ↗

Phase II Mental Disorders Authorised 22/06/2026

Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study

Posttraumatic stress disorder

ARQ National Psychotrauma Centrum

12 participants planned

Netherlands

2025-521488-11-00 on CTIS ↗

Phase II Bacterial Infections and Mycoses Authorised 22/06/2026

Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial

Fracture-Related Infection

Amsterdam UMC Stichting

50 participants planned

Netherlands

2026-525871-24-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 22/06/2026

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

Osteogenesis Imperfecta

Angitia Inc. Ltd.

40 participants planned

Netherlands · France · Denmark

2025-522951-24-00 on CTIS ↗

Phase IV Digestive System Diseases Authorised 19/06/2026

Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.

Post-ERCP Pancreatitis

Amsterdam UMC Stichting

520 participants planned

Netherlands

2025-522900-26-00 on CTIS ↗

Phase I Not possible to specify Authorised 19/06/2026

A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity

Cardiometabolic

Novo Nordisk A/S

128 participants planned

Netherlands

2026-525179-26-00 on CTIS ↗

Phase III Respiratory Tract Diseases Authorised 17/06/2026

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis

Bristol-Myers Squibb Services Unlimited Company

318 participants planned

Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany

2025-522373-10-00 on CTIS ↗

Phase I Skin and Connective Tissue Diseases Authorised 16/06/2026

A First‑in‑Human Phase 1 Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

Healthy volunteers

Arcus Biosciences Inc.

130 participants planned

Netherlands

2026-526279-52-00 on CTIS ↗

Phase II Respiratory Tract Diseases Authorised 16/06/2026

RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer

Stage I non-small cell lung cancer

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

30 participants planned

Netherlands

2025-524305-32-00 on CTIS ↗

Phase II Musculoskeletal Diseases Authorised 16/06/2026

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Duchenne Muscular Dystrophy

Entrada Therapeutics Inc.

56 participants planned

Belgium · Italy · Netherlands · Spain

2025-525124-10-00 on CTIS ↗

Phase III Neoplasms Authorised 16/06/2026

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2

AstraZeneca AB

516 participants planned

France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands

2024-519787-40-00 on CTIS ↗

Phase I/II Neoplasms Authorised 16/06/2026

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

Metastatic Prostate Cancer

AstraZeneca AB

45 participants planned

Belgium · Spain · Poland · Italy · Netherlands

2025-520626-37-00 on CTIS ↗

Phase III Neoplasms Authorised 16/06/2026

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Stage I NSCLC

Merck Sharp & Dohme LLC

283 participants planned

Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain

2025-522643-18-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 15/06/2026

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

Musculoskeletal diseases

Sanofi-Aventis Recherche & Developpement

177 participants planned

France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain

2024-511296-15-00 on CTIS ↗

Phase III Musculoskeletal Diseases Authorised 15/06/2026

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Limb Girdle Muscular Dystrophy (LGMD) Type 2I

ML Bio Solutions Inc.

35 participants planned

Germany · Denmark · Netherlands · Italy · Norway

2025-524371-23-00 on CTIS ↗

Phase III Neoplasms Authorised 12/06/2026

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation

Merck Sharp & Dohme LLC

88 participants planned

Italy · Netherlands · France · Germany · Spain · Poland · Greece

2025-522038-29-00 on CTIS ↗

Phase III Neoplasms Authorised 12/06/2026

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed/refractory B-cell Acute Lymphoblastic Leukemia

Merck Sharp & Dohme LLC

109 participants planned

Greece · Netherlands · Sweden · France · Italy · Spain · Denmark

2025-522267-15-00 on CTIS ↗

Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

210 participants planned

Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria

2025-523674-16-00 on CTIS ↗